{Reference Type}: Case Reports
{Title}: The first report of leukocytoclastic vasculitis induced by once-weekly subcutaneous semaglutide.
{Author}: Pinheiro MM;de Souza LG;Nunes GP;Martin IF;de Oliveira YU;Pinheiro FMM;Costa LN;Caprio M;Della-Morte D;Infante M;
{Journal}: Curr Med Res Opin
{Volume}: 40
{Issue}: 9
{Year}: 2024 Sep 2
{Factor}: 2.705
{DOI}: 10.1080/03007995.2024.2386047
{Abstract}: <B>UNASSIGNED: </B>Leukocytoclastic vasculitis (LCV) is a small vessel vasculitis involving arterioles, capillaries and postcapillary venules. LCV is generally confined to the skin, with extracutaneous manifestations occurring less frequently. LCV has multiple potential etiologies. Indeed, histological LCV can be found in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, immune complex vasculitis, vasculitis associated with systemic diseases (i.e. sarcoidosis, Sjögren's syndrome, rheumatoid arthritis, and systemic lupus erythematosus), or in vasculitis associated with cancer, infections, sepsis and use of certain medications. LCV can also be idiopathic in up to 50% of cases.<BR><B>UNASSIGNED: </B>Semaglutide is a glucagon-like peptide 1 (GLP-1) receptor agonist used for management of type 2 diabetes mellitus (T2DM), obesity and overweight associated with one or more weight-related comorbidities. A case of drug-induced LCV has already been described with the use of once-daily oral semaglutide. Herein, we describe the first case of skin-limited LCV induced by once-weekly subcutaneous semaglutide in a 73-year-old man with T2DM, who experienced the complete resolution of the skin lesions shortly after the discontinuation of semaglutide therapy.<BR><B>UNASSIGNED: </B>Future prospective studies, adverse event reporting and post-marketing surveillance will certainly contribute to establishing if LCV represents a less rare than expected side effect of both oral and subcutaneous semaglutide formulations.